BrainStorm Cell Therapeutics remains focused on commercializing its lead autologous stem cell therapy NurOwn® for ALS and progressive multiple sclerosis, leveraging proprietary neurotrophic factor-secreting MSC technology. The latest quarterly filing reveals severe liquidity pressures, with cash of only $15K against current liabilities exceeding $11 million, reinforcing reliance on external financing to continue operations. Regulatory progress such as the FDA Special Protocol Agreement (SPA) for the Phase 3b trial and patent allowances underpin its clinical moat, though risks around approval uncertainty and financial sustainability persist.